BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 23, 2010
 |  BC Week In Review  |  Company News  |  Deals

Quark, Novartis deal

Quark granted Novartis an option to license exclusive, worldwide rights to QPI-1002. The short interfering RNA (siRNA) inhibitor of p53 expression is in Phase II testing to prevent delayed graft function in renal...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >